Your session is about to expire
← Back to Search
AGAR T Cell Therapy for Pediatric Solid Cancers
Study Summary
This trial is for patients with solid tumors that have a protein called GPC3 on the surface of the tumor cells.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not on high doses of steroids or can stop them 24 hours before CAR T cell therapy.My tumor is GPC3-positive with more than 25% of cells affected and a high intensity score.I have had an organ transplant.Your Child-Pugh-Turcotte score is less than 7 (for patients with liver cancer only).You are expected to live for at least 16 weeks.Your kidneys, liver, and blood need to work well. You must have a certain level of blood cells, oxygen, and be recovered from previous treatments. If you are sexually active, you need to use effective birth control for 3 months after the treatment.You have HIV.My liver cancer is at an early to intermediate stage.I do not have any infections that are not responding to treatment.I am allergic to mouse protein products or have human anti-mouse antibodies.I am between 1 and 21 years old.I can care for myself but may need occasional help.I do not have any active infections, except possibly Hepatitis B or C.
- Group 1: AGAR T cells
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the age range of participants in this trial extending beyond 40 years old?
"The permitted age range for patient recruitment in this medical trial is between 1 and 21 years of age."
What maladies has AGAR T cells been established to mitigate?
"AGAR T cells are primarily used to combat multiple sclerosis, yet it may also be effective at treating conditions such as lymphoma, leukemia, myelocytic diseases, acute illnesses and retinoblastoma."
Has AGAR T cell technology been tested in another trial prior to this one?
"Presently, 889 clinical trials are being conducted for AGAR T cells with 161 of them at Phase 3. 28443 sites across the world have studies underway regarding this treatment, though most locations are in Philadelphia, Pennsylvania."
For what population is enrollment being accepted for this research study?
"Qualified applicants for this clinical trial must have rhabdomyosarcoma and be between one year of age up to twenty-one. In total, 24 patients are sought after by the research team."
How many volunteers have been included in this experiment?
"Affirmative, the clinicaltrials.gov data suggest that this study is currently open for recruitment; it was first posted on December 8th 2021 and recently revised on April 18th 2022. The research seeks 24 participants from a single medical facility."
Are applications to participate in this experiment currently being accepted?
"Indeed, research posted on clinicaltrials.gov attests that this investigation is currently seeking participants. It was initially published on December 8th 2021 and has been amended as of April 18th 2022. The trial needs to enrol 24 patients from a single medical centre."
Has the FDA granted authorization to use AGAR T cells therapeutically?
"Our team has calculated the safety of AGAR T cells to be a 1, as this is an early phase trial with only limited information about its efficacy and safety."
Share this study with friends
Copy Link
Messenger